REC-4881-221: For patients with an AXIN1 or APC mutation for locally advanced or metastatic cancer

Therapy on Trial: REC-4881 Drug

Study Information

Study Title

A Phase 2, Open Label Study of REC-4881 in Participants with Unresectable Locally Advanced or Metastatic Cancer with AXIN1 or APC Mutation (LILAC Study)

Study Summary

The purpose of this clinical trial is to evaluate the safety and tolerability of REC-4881 as well as the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR).

Disease State

Metastatic Disease with APC or AXIN1 Mutation

Principal Investigator

Myron Bednar, MD

Phase II

If you have any questions regarding this study or think that you or your loved one may be eligible, please contact our Clinical Trial Coordinator by dialing 908.237.1201 extension 262.

Contact HHO

All questions and feedback are welcome, anytime.

    About HHO

    Hunterdon Hematology Oncology is a community oncology group, dedicated to fighting cancer in this community and across the region. Our Doctors, Physician’s Assistants and Nurses work tirelessly. They fight hard so that you can win.


    Sign up for the HHO newsletter to stay up to date on the latest news within the practice and the community.

      © HHO 2022. All rights reserved. Designed by DRAW